Total Payments
$7,137
2024 Payments
$1,979
Companies
61
Transactions
353
Medicare Patients
11,483
Medicare Billing
$4.2M
Payment Breakdown by Category
Food & Beverage$5,849 (81.9%)
Other$681.53 (9.5%)
Education$606.93 (8.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,849 | 326 | 81.9% |
| Long term medical supply or device loan | $681.53 | 7 | 9.5% |
| Education | $606.93 | 20 | 8.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,163 | 38 | $0 (2024) |
| PFIZER INC. | $629.87 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $438.66 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $320.50 | 14 | $0 (2024) |
| Sirtex Medical Inc | $295.82 | 5 | $0 (2024) |
| Genentech USA, Inc. | $275.85 | 16 | $0 (2020) |
| Merck Sharp & Dohme LLC | $247.81 | 15 | $0 (2023) |
| Janssen Biotech, Inc. | $247.51 | 12 | $0 (2024) |
| Incyte Corporation | $224.98 | 7 | $0 (2024) |
| Medtronic, Inc. | $221.36 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,979 | 64 | Novartis Pharmaceuticals Corporation ($743.83) |
| 2023 | $1,371 | 63 | Novartis Pharmaceuticals Corporation ($129.93) |
| 2022 | $485.34 | 25 | Medtronic, Inc. ($91.05) |
| 2021 | $164.11 | 6 | Lilly USA, LLC ($100.39) |
| 2020 | $269.44 | 14 | Genentech USA, Inc. ($58.27) |
| 2019 | $615.89 | 36 | Novartis Pharmaceuticals Corporation ($86.75) |
| 2018 | $869.44 | 75 | PFIZER INC. ($142.41) |
| 2017 | $1,383 | 70 | Sirtex Medical Inc ($240.90) |
All Payment Transactions
353 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.41 | General |
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Oncology | ||||||
| 11/18/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Genetic Disease | ||||||
| 11/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $25.83 | General |
| Category: Hematology/Oncology | ||||||
| 11/01/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $7.57 | General |
| Category: HEMATOLOGY | ||||||
| 10/31/2024 | Inari Medical, Inc. | CT THROMBECTOMY SYSTEM KIT (Device), FLOWTRIEVER CATHETER, S | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: VTE | ||||||
| 10/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.34 | General |
| 09/19/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.48 | General |
| Category: Hematology | ||||||
| 08/26/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Monoclonal Antibody | ||||||
| 07/22/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $24.15 | General |
| Category: Oncology | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/15/2024 | PFIZER INC. | INLYTA (Drug), IBRANCE, TALZENNA | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,869 | 94,092 | $5.4M | $1.1M |
| 2022 | 52 | 2,324 | 90,530 | $5.4M | $833,906 |
| 2021 | 51 | 3,166 | 122,423 | $6.4M | $1.1M |
| 2020 | 50 | 3,124 | 127,121 | $6.4M | $1.1M |
Total Patients
11,483
Total Services
434,166
Medicare Billing
$4.2M
Procedure Codes
203
All Medicare Procedures & Services
203 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 13,300 | $1.8M | $568,607 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 304 | 1,423 | $523,664 | $131,696 | 25.1% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 20 | 3,850 | $900,830 | $129,963 | 14.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 69 | 555 | $392,385 | $53,713 | 13.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 35 | 42 | $201,684 | $45,774 | 22.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 13 | 2,040 | $135,000 | $37,195 | 27.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 89 | 368 | $90,896 | $21,511 | 23.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 83 | 292 | $91,396 | $13,740 | 15.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 14 | 109 | $54,500 | $13,420 | 24.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 285 | 1,217 | $77,888 | $12,587 | 16.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 308 | 1,527 | $54,972 | $11,620 | 21.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 278 | 1,162 | $23,240 | $9,761 | 42.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 73 | 820 | $88,560 | $9,504 | 10.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 74 | 74 | $41,810 | $8,095 | 19.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 137 | $47,128 | $6,650 | 14.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 48 | 290 | $45,530 | $6,291 | 13.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 50 | $34,700 | $6,251 | 18.0% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 48 | 34,600 | $69,200 | $5,513 | 8.0% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 12 | 1,725 | $43,125 | $5,435 | 12.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 40 | 48 | $31,536 | $4,312 | 13.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 44 | $20,680 | $4,036 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 76 | $19,000 | $3,999 | 21.0% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 29 | 90 | $12,870 | $3,153 | 24.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 28 | 116 | $18,676 | $2,476 | 13.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 22 | 19,800 | $99,000 | $2,420 | 2.4% |
About Dr. Akbar Rizvi, MD
Dr. Akbar Rizvi, MD is a Hematology & Oncology healthcare provider based in Mckinney, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1225023948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Akbar Rizvi, MD has received a total of $7,137 in payments from pharmaceutical and medical device companies, with $1,979 received in 2024. These payments were reported across 353 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($5,849).
As a Medicare-enrolled provider, Rizvi has provided services to 11,483 Medicare beneficiaries, totaling 434,166 services with total Medicare billing of $4.2M. Data is available for 4 years (2020–2023), covering 203 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Mckinney, TX
- Active Since 09/19/2005
- Last Updated 02/04/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1225023948
Products in Payments
- KISQALI (Drug) $753.26
- SIR-Spheres Microspheres (Device) $295.82
- OPDIVO (Biological) $276.47
- KEYTRUDA (Biological) $214.37
- Optune (Device) $201.34
- OSTEOCOOL RF ABLATION SYSTEM (Device) $198.91
- SARCLISA (Biological) $167.51
- BOSULIF (Drug) $158.59
- IBRANCE (Drug) $148.80
- DARZALEX (Biological) $142.87
- IMFINZI (Biological) $137.51
- BESREMI (Drug) $110.77
- ZYTIGA (Drug) $110.65
- XARELTO (Drug) $110.07
- Avastin (Biological) $106.25
- XALKORI (Drug) $105.99
- AFINITOR (Drug) $100.96
- JAKAFI (Drug) $99.57
- LYNPARZA (Drug) $92.81
- ELIQUIS (Drug) $88.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mckinney
Dr. Sultan Chowdhary, Md, MD
Hematology & Oncology — Payments: $13,456
Hematology & Oncology $13,456
Dr. Nithya Palanisamy, Md, MD
Hematology & Oncology — Payments: $9,411
Hematology & Oncology $9,411
Amanullah Khan, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $3,366
Hematology & Oncology $3,366
Dr. Arisha Patel, Md, Mba, MD, MBA
Hematology & Oncology — Payments: $112.89
Hematology & Oncology $112.89